Printer Friendly

Mortise Medical passes US FDA clearance for LigaMetrics Suture Anchor System in ligament surgery.

M2 EQUITYBITES-September 27, 2017-Mortise Medical passes US FDA clearance for LigaMetrics Suture Anchor System in ligament surgery


Medical device company Mortise Medical reported on Tuesday the receipt of US FDA 510(k) clearance for its innovative LigaMetrics Suture Anchor System for precision in ligament and tendon surgery.

The company added that the Mortise Medical LigaMetrics Suture Anchor System is the first and only knotless suture anchor that provides precise, measured tension control of the suture repair construct as well as unmatched surgeon control for achieving optimal stabilisation to facilitate healing of injured ligaments and tendons.

Designed specifically for connecting to and locking suture tape that is attached either to soft tissue or attached to a conventional suture anchor, the surgical technique for the LigaMetrics Suture Anchor System is designed to place maximum control of the final repair construct in the hands of the surgeon, said the company.

According to the company, the LigaMetrics Suture Anchor is fully seated into the bone and then the Metrics Tensioner is engaged with the anchor and suture tape to apply measured, controlled tension to the repair construct. The stability and range of motion assessments can be conducted and further fine adjustments to tension can be made by the surgeon to optimize the quality of the repair.

Following optimal tension, the torque controlled locking feature of the LigaMetrics Suture Anchor is activated to lock the suture tape to the anchor, eliminating the need to for knot tying, concluded the company.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 27, 2017
Previous Article:PS Business Parks declares partial redemption of about 62.9% outstanding depositary shares representing interests in series T preferred stock at...
Next Article:Lannett awarded US FDA approval for Dexmethylphenidate Hydrochloride Tablets in 2.5 mg, 5 mg & 10 mg.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters